Q-omics provides the consensus-scored EEF1GP1 profile across patient tissues and cancer cell-line models. EEF1GP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EEF1GP1 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, EEF1GP1 RNA expression shows 12,562 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, PAAD, and PDAC as cancer lineages where EEF1GP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EEF1GP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EEF1GP1 survival associations across molecular data types. EEF1GP1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EEF1GP1 RNA expression–survival associations across cancer types. High EEF1GP1 expression shows unfavorable associations in KIRC, BLCA, ACC and UVM, but favorable associations in CHOL and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EEF1GP1 RNA expression.
This table summarizes EEF1GP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for EEF1GP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EEF1GP1 shows higher tumor expression in PAAD, CHOL, LUAD and LIHC. The PAAD box plot shows higher EEF1GP1 RNA expression in tumor versus normal tissue (log2 FC = +0.485, t-test p = .004).
This table shows molecular features associated with EEF1GP1 in patient tissues and cancer cell lines. In patient samples, EEF1GP1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
